Complimentary Commercial Content
Ceva Animal Health U.S. announced PANOQUELL®-CA1 is now available in the U.S. It is the first and only drug conditionally approved by the FDA for management of the symptoms associated with acute onset of canine pancreatitis.
The drug will address the inflammation associated with acute onset of canine pancreatitis, an important, unmet medical need for a common, unpredictable disease which has traditionally been managed only with supportive care.
PANOQUELL®-CA1 is a welcome and valuable product to support recovery and its unique mechanism of action is an incredibly exciting innovation in veterinary medicine.” – Susanne Heartsill, DVM, DABVP
Source: Ceva Animal Health U.S. May 16, 2023. Link. Fuzapladib sodium has been approved for acute canine pancreatitis in Japan since 2018. Developed by ISHIHARA SANGYO KAISHA, LTD. (ISK) and registered by ISK Animal Health, LLC in the U.S. to treat Acute Canine Pancreatitis (ACP), the product will be marketed and distributed in the U.S. by Ceva Animal Health, LLC.